Venture has made over 1 trades of the Intellia Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Venture sold 21,132 units of NTLA stock worth 293,946$ on 9 March 2017.
The largest trade Venture's ever made was selling 21,132 units of Intellia Therapeutics Inc stock on 9 March 2017 worth over 293,946$. On average, Venture trades about 21,132 units every 0 days since 2017.
You can see the complete history of Venture P stock trades at the bottom of the page.
Venture's mailing address filed with the SEC is 25 FIRST STREET, SUITE 30325 FIRST STREET, SUITE 303, , CAMBRIDGECAMBRIDGE, MAMA, 0214102141.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over 210,567,884$ worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth 23,117,886$ . The most active insiders traders include Carl L Gordon、Jean Francois Formela、Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of 1,357,638$. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth 9,287$.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: